z-logo
open-access-imgOpen Access
SYNTHESIS, SPECTRAL ANALYSIS, ANTIBACTERIAL ACTIVITY AND MOLECULAR DOCKING STUDIES OF SOME NOVEL DERIVATIVES OF COMBINED TETRAZOLE AND THIOSEMICARBAZIDE MOIETIES
Author(s) -
D. Bhakiaraj,
T. Elavarasan,
M. Mathavan,
S. Megala,
E. Enbaraj,
M. Gopalakrishnan
Publication year - 2021
Publication title -
journal of advanced scientific research
Language(s) - English
Resource type - Journals
ISSN - 0976-9595
DOI - 10.55218/jasr.s1202112423
Subject(s) - docking (animal) , chemistry , staphylococcus aureus , tetrazole , triclosan , antimicrobial , escherichia coli , combinatorial chemistry , antibacterial activity , stereochemistry , aryl , proton nmr , carbon 13 nmr , biochemistry , organic chemistry , bacteria , biology , medicine , genetics , nursing , pathology , gene , alkyl
A few novel tetrazolyl thiosemicarbazide derivatives namely, 1-(1-(1-aryl-1H-tetrazol-5-yl)ethylidene) thiosemicarbazides (5a-5g) were synthesized and their structures were confirmed by FT-IR, 1H-NMR and 13C-NMR studies. The synthesized compounds were screened against various microbial strains for their antimicrobial activities and the results shows good activities. The compounds 5b and 5f were showing promising activity against Staphylococcus aureus and Escherichia coli. Additionally, Molecular docking studies were also carried out for these Tetrazolylthiosemicarbazide derivatives and were docked against Enoyl-[acyl-carrier-protein] reductase of Staphylococcus aureus (saFabI), obtained from Protein Data Bank (4ALI) as this structure was resolved in complex with NADP and triclosan. From the docking results, the compounds 5b, 5d and 5f are found to be strong binders with saFabI and having stronger binding affinity with saFabI than triclosan-saFabI complex. Therefore, it can be inferred that tetrazolylthiosemicarbazide derivatives, in specific, compounds 5f, 5b and 5d could be taken up for further evaluation towards novel drug design against Staphylococcus aureus.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here